AR056471A1 - Formulaciones de acetato de bazedoxifeno - Google Patents

Formulaciones de acetato de bazedoxifeno

Info

Publication number
AR056471A1
AR056471A1 ARP060103666A ARP060103666A AR056471A1 AR 056471 A1 AR056471 A1 AR 056471A1 AR P060103666 A ARP060103666 A AR P060103666A AR P060103666 A ARP060103666 A AR P060103666A AR 056471 A1 AR056471 A1 AR 056471A1
Authority
AR
Argentina
Prior art keywords
weight
pharmaceutical formulation
constitutes
composition according
component
Prior art date
Application number
ARP060103666A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37772333&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR056471(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR056471A1 publication Critical patent/AR056471A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La presente está dirigida a formulaciones de acetato de bazedodoxifeno que tienen una conversion polimorfica reducida, a composiciones que las contienen, a sus preparaciones y sus usos. Reivindicacion 1: Una composicion farmacéutica caracterizada porque comprende una cantidad farmacéuticamente eficaz de acetato de bazedoxifeno y un sistema de vehículos o excipientes, donde el sistema de vehículos o excipientes comprende: a) un primer componente relleno/diluyente que constituye de alrededor de 5% a alrededor de 85% en peso de la formulacion farmacéutica; b) un segundo componente relleno/diluyente opcional que constituye de alrededor de 5% a alrededor de 85% en peso de la formulacion farmacéutica; c) un componente antioxidante opcional que constituye hasta alrededor de 15% en peso de la formulacion farmacéutica; d) un componente agente deslizante/desintegrante que constituye de alrededor de 0,01% a alrededor de 10% en peso de la formulacion farmacéutica; y e) un componente lubricante que constituye de alrededor de 0,01% a alrededor de 10% en peso de la formulacion farmacéutica. Reivindicacion 29: Una tableta caracterizada porque comprende una composicion de acuerdo con cualquiera de las reivindicaciones 1 a 28. Reivindicacion 31: Una cápsula caracterizada porque contiene una composicion de acuerdo con cualquiera de las reivindicaciones 1 a 28. Reivindicacion 32: Un proceso no acuoso para prepara una composicion farmacéutica de acuerdo con cualquiera de las reivindicaciones 1 a 28, el proceso caracterizado porque comprende mezcla, directa, granulacion seca o compactacion por rodillos. Reivindicacion 38: Un producto caracterizado porque se fabrica por el proceso de cualquiera de las reivindicaciones 32 a 37.
ARP060103666A 2005-08-24 2006-08-23 Formulaciones de acetato de bazedoxifeno AR056471A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71076105P 2005-08-24 2005-08-24

Publications (1)

Publication Number Publication Date
AR056471A1 true AR056471A1 (es) 2007-10-10

Family

ID=37772333

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103666A AR056471A1 (es) 2005-08-24 2006-08-23 Formulaciones de acetato de bazedoxifeno

Country Status (21)

Country Link
US (1) US7771744B2 (es)
EP (1) EP1919456A2 (es)
JP (2) JP2009506053A (es)
KR (2) KR101584674B1 (es)
CN (1) CN101304731B (es)
AR (1) AR056471A1 (es)
AU (1) AU2006283121A1 (es)
BR (1) BRPI0615341A2 (es)
CA (1) CA2620174A1 (es)
CR (1) CR9746A (es)
EC (1) ECSP088214A (es)
GT (1) GT200600383A (es)
IL (2) IL189648A (es)
MX (1) MX2008002484A (es)
NO (1) NO20080991L (es)
PE (1) PE20070425A1 (es)
RU (1) RU2417084C2 (es)
SV (1) SV2008002825A (es)
TW (1) TW200738281A (es)
WO (1) WO2007024961A2 (es)
ZA (1) ZA200801742B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06011685A (es) * 2004-04-08 2006-12-14 Wyeth Corp Formulaciones de dispersiones solidas de acetato de bazedoxifeno.
AU2006283121A1 (en) * 2005-08-24 2007-03-01 Wyeth Bazedoxifene acetate formulations and manufacturing process thereof
AU2007232098A1 (en) * 2006-03-31 2007-10-11 Rubicon Research Private Limited Directly compressible composite for orally disintegrating tablets
WO2008079342A2 (en) * 2006-12-21 2008-07-03 Mallinckrodt Inc. Composition of and method for preparing orally disintegrating tablets
US20100016582A1 (en) * 2008-02-11 2010-01-21 Wyeth Methods of converting polymorphic form b of bazedoxifene acetate to polymorphic form a of bazedoxifene acetate
ITMI20091109A1 (it) 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
CA2818068C (en) * 2010-11-30 2019-06-11 Wista Laboratories Ltd. Formulations comprising methylthioninium chloride
EP2471770A1 (en) * 2010-12-28 2012-07-04 Sandoz Ag Method of preparing polymorphic pure form A of bazedoxifene acetate
WO2013182170A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Enhancement of dissolution rate from pharmaceutical composition comprising bazedoxifene acetate
WO2013182169A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Process of preparation of an antioxidant-free polymorphically and chemically stable formulation of bazedoxifene acetate
CN103877581B (zh) * 2014-03-24 2016-03-02 江苏知原药业有限公司 一种性能优异的乙酸巴多昔芬缓释制剂
WO2018182205A1 (ko) * 2017-03-30 2018-10-04 한미약품 주식회사 바제독시펜 아세테이트를 함유하는 안정화된 약제학적 조성물
KR101940569B1 (ko) * 2017-05-24 2019-01-21 아주대학교산학협력단 바제독시펜 또는 이의 약학적으로 허용가능한 염을 포함하는 약학 조성물
CN112076163B (zh) * 2019-06-14 2023-06-20 四川科伦药物研究院有限公司 一种醋酸巴多昔芬片的药物组合物及其制备方法
CN111004165A (zh) * 2019-12-03 2020-04-14 南京正济医药研究有限公司 一种醋酸巴多昔芬晶型a的制备方法
CN112754999A (zh) * 2021-01-23 2021-05-07 郑州泰丰制药有限公司 一种醋酸巴多昔芬组合物及醋酸巴多昔芬薄膜衣片制备方法
CN113368075A (zh) * 2021-06-29 2021-09-10 郑州泰丰制药有限公司 一种醋酸巴多昔芬片及其制备方法
CA3229700A1 (en) * 2021-08-23 2023-03-02 Jan Brabek Treatment of covid-19

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686094A (en) * 1991-04-01 1997-11-11 Theratech, Inc. Controlled release formulations for the treatment of xerostomia
CN1119998C (zh) * 1995-06-22 2003-09-03 阿克佐诺贝尔公司 去氧孕烯的压制干颗粒片
US5998402A (en) * 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US6479535B1 (en) * 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
CN1429222A (zh) 2000-02-17 2003-07-09 安姆根有限公司 激酶抑制剂
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
CN1658868A (zh) * 2002-06-13 2005-08-24 惠氏公司 巴泽昔芬治疗方案
RU2006123939A (ru) 2004-01-13 2008-02-20 Вайет (Us) Лечение остеопороза, связанного с терапией ингибиторами ароматазы
JP2007532548A (ja) 2004-04-07 2007-11-15 ワイス バゼドキシフェンアセテートの結晶質多形体
SG151331A1 (en) 2004-04-07 2009-04-30 Wyeth Corp Crystalline polymorph of a bazedoxifene acetate
CN1938272A (zh) * 2004-04-07 2007-03-28 惠氏公司 巴泽多昔芬醋酸盐的结晶多晶型物
MXPA06011685A (es) * 2004-04-08 2006-12-14 Wyeth Corp Formulaciones de dispersiones solidas de acetato de bazedoxifeno.
AU2006283121A1 (en) * 2005-08-24 2007-03-01 Wyeth Bazedoxifene acetate formulations and manufacturing process thereof

Also Published As

Publication number Publication date
MX2008002484A (es) 2008-04-07
IL189648A0 (en) 2008-08-07
KR20080043853A (ko) 2008-05-19
IL189648A (en) 2014-07-31
JP2009506053A (ja) 2009-02-12
US20070048374A1 (en) 2007-03-01
AU2006283121A1 (en) 2007-03-01
WO2007024961A2 (en) 2007-03-01
US7771744B2 (en) 2010-08-10
NO20080991L (no) 2008-05-15
JP2013209419A (ja) 2013-10-10
CN101304731A (zh) 2008-11-12
CA2620174A1 (en) 2007-03-01
GT200600383A (es) 2007-03-29
TW200738281A (en) 2007-10-16
KR20140088917A (ko) 2014-07-11
BRPI0615341A2 (pt) 2011-05-17
ZA200801742B (en) 2010-10-27
CN101304731B (zh) 2012-06-20
SV2008002825A (es) 2008-06-30
EP1919456A2 (en) 2008-05-14
CR9746A (es) 2008-08-21
KR101584674B1 (ko) 2016-01-13
IL233392A (en) 2017-02-28
WO2007024961A3 (en) 2007-06-28
IL233392A0 (en) 2014-08-31
RU2008107580A (ru) 2009-09-27
RU2417084C2 (ru) 2011-04-27
PE20070425A1 (es) 2007-07-02
ECSP088214A (es) 2008-03-26

Similar Documents

Publication Publication Date Title
AR056471A1 (es) Formulaciones de acetato de bazedoxifeno
ES2524320T3 (es) Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
EP3916091A3 (en) Dry powder composition comprising long-chain rna
SG158870A1 (en) Bendamustine pharmaceutical compositions for lyophilisation
EA201001852A1 (ru) Твердые фармацевтические составы, содержащие bibw 2992
CL2011000653A1 (es) Compuestos derivados del acido 1-amino-2-ciclobutil-etil-boronico; composicion farmaceutica; polvo liofilizado y metodo para obtenerlo; y uso en el tratamiento del cancer.
CO7101246A2 (es) Compuesto de carbamato y preparación y uso de los mismos
BRPI0608877B8 (pt) composição imunogênica de rotavírus líquida, uso de um antígeno de rotavírus, um açúcar e um carboxilato, e, método para a preparação de uma composição de rotavírus líquida
MX2008009357A (es) Una composicion solida de taxano liofilizada, un procedimiento para preparar dicha composicion solida, una formulacion farmaceuctica y un conjunto (kit) de dicha formulacion.
GT201200024A (es) Formulación subcutánea de anticuerpo anti-her2
WO2012075081A3 (en) High-strength testosterone undecanoate compositions
BRPI0809164B8 (pt) Composição para administração tópica e composição farmacêutica compreendendo a referida composição
CU20060153A7 (es) Nueva forma cristalina v de agomelatina, procedimiento para su preparación y composiciones farmacéuticas que las contienen
CA2716874A1 (en) A pharmaceutical composition and its use in the preparation of a medicament for the treatment of cerebrovascular diseases
GT201000095A (es) Producto de dispersión sólida que contiene un compuesto a base de n-aril urea
WO2011116139A3 (en) Improved pharmaceutical compositions comprising cck- 8 and methods of delivery
TW200640502A (en) Tablets with improved drug substance dispersibility
WO2015104292A3 (en) Compounds for use in treating or preventing cancerous diseases
MX2017015879A (es) Composiciones de hidroxipropil beta-ciclodextrina y metodos.
PH12015502556A1 (en) Modified release formulation
BRPI0518789A2 (pt) formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, produto, e, cÁpsula ou tablete
NZ594035A (en) Solid oral formulations of a pyridopyrimidinone
MX2010004556A (es) Formulacion farmaceutica de acido clavulanico.
MX2019008773A (es) Derivados de caliqueamicina y conjugados anticuerpo-farmaco de los mismos.
MX2020005117A (es) Formulaciones peptídicas de liberación sostenida.

Legal Events

Date Code Title Description
FC Refusal